Judah Folkman, MD, whose groundbreaking work involving tumor angiogenesis led to the development of targeted therapies for the disease, died Jan. 14 in Denver of an apparent heart attack. He was 74.
Judah Folkman, MD, whose groundbreaking work involving tumor angiogenesis led to the development of targeted therapies for the disease, died Jan. 14 in Denver of an apparent heart attack. He was 74.
At the time of his death, Dr. Folkman was director of the vascular biology program, Julia Dyckman Andrus Professor of Pediatric Surgery, and professor of cell biology at Children’s Hospital in Boston, where he formerly was surgeon-in-chief.
As a U.S. Navy lieutenant at the National Naval Medical Center in Bethesda, MD, Dr. Folkman noticed that tumors in rodents died when deprived of their blood supply. His research identified two natural compounds, endostatin and angiostatin, capable of shrinking and eradicating cancer in mice. His discoveries were the genesis for targeted therapies for cancer and age-related macular degeneration.
Dr. Folkman graduated cum laude from The Ohio State University, Columbus, and magna cum laude in medicine at Harvard Medical School, Boston. He was the author of 389 original peer-reviewed papers and 106 book chapters and monographs.
In an interview published in March 2001, Dr. Folkman told Urology Times: “There are still a few naysayers who tell me that they firmly believe that tumors do not need new blood vessels to grow to be lethal. Naysayers are common, and I think they just come with the territory.”
He is survived by his wife, Paula, two daughters, and a granddaughter.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.